Concord Drugs Limited reported consolidated results for the quarter ended June 2026 with net sales of Rs 20.94 crore, up 53.89% from Rs 13.61 crore in June 2025, and net profit of Rs 1.11 crore, up 845.67% from Rs 0.12 crore. EBITDA rose 124.51% to Rs 2.29 crore from Rs 1.02 crore and EPS increased to Rs 0.85 from Rs 0.12. Sequentially, sales fell from Rs 37.89 crore in March 2026 while profit rose from Rs 0.53 crore.